Table 1.

Summary of results from reported trials evaluating autologous stem-cell transplantation in patients with HIV-related lymphoma

Author, year of publication	Nature of study	No. patients enrolled,	No. received AuSCT/histology	Dz status at AuSCT	Regimen	HAART	CR rate, %	Median DFS	TRM
Re et al. 2003 [11]	Multicenter prospective	16	4 HL	1 PR	BEAM	Yes	89%*	67% at 8 mos.*	0%
			6 NHL	2 1st relapse 3 2nd relapse 4 refractory
Gabarre et al. 2004 [14]	Retrospective review	14	6 HL	9 1st relapse	Various regimens of  chemotherapy±TBI	Yes	71%	29% at 25 mos.	0%
			8 NHL	1 2nd relapse 1 3rd relapse 1 4th relapse 2 refractory
Krishnan et al. 2005 [12••]	Single institution prospective		2 HL	4 CR1	BEC (n=17)	Yes	90%	85% at 32 mos.	5%
		20	18 NHL	1 CR2 1 CR3 3 PR 9 1st relapse 2 2nd relapse	fTBI +VP16/Cy (n=3)
Serrano et al. 2005 [13•]	Multicenter prospective	14	3 HL	6 CR1	BEAM (n=10)	Yes	73%	65% at 30 mos.	0%
			11 NHL	4 CR2 4 PR	BEAC (n=1)
Spitzer et al. (in press) [15]	Multicenter prospective	27	5 HL	6 CR	Dose-adjusted Bu/Cy	Yes	53%	50% at 6 mos.	5%
			15 NHL	2 PR 12 CS

AuSCT, autologous stem-cell transplantation; BEAC, carmustine, etoposide, cytarabine, cyclophosphamide; BEAM, carmustine, etoposide, cytarabine, melphalan; BEC, carmustine, etoposide, cyclophosphamide; BusuBu/CY, busulfan, cyclophosphamide; CR, complete response; CS, chemosensitive disease (improvement of at least 25% in bidimensional tumor measurements or an improvement in evaluable disease sustained over 4 weeks); DFS, disease-free survival; Dz, disease; fTBI + VP-16/Cy, fractionated total body irradiation, etoposide, cyclophosphamide; HL, Hodgkin’s lymphoma; mos, months; NHL, non-Hodgkin’s lymphoma; PR, partial response; TRM, transplant related mortality.

^*Response is based on eight patients, so it is too early to assess response in one patient.